[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342515-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342515-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","circulating-tumor-dna-enables-sensitive-detection-of-actionable-gene-fusions-and-rearrangements-across-cancer-types","Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types","","Liquid biopsy profiling of circulating tumor DNA (ctDNA) is evaluated for detecting gene fusions and rearrangements that drive cancer biology and enable targeted treatment. The study analyzes liquid biopsy (LBx) from 53,842 patients spanning 66 solid tumor types using FoundationOneLiquid CDx, comparing results with tissue biopsy (TBx) tested by FoundationOneCDx. Pathogenic rearrangements are found in 14% of LBx, including gain-of-function oncogene events and loss-of-function events. Detection rates in LBx are comparable to TBx when tumor fraction is ≥1%, supporting ctDNA-based testing when tissue is unavailable and informing limits of confirmatory testing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/circulating-tumor-dna-enables-sensitive-detection-of-actionable-gene-fusions-and-rearrangements-across-cancer-types/342515/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/circulating-tumor-dna-enables-sensitive-detection-of-actionable-gene-fusions-and-rearrangements-across-cancer-types/342515.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about circulating tumor DNA?","Question",{"text":63,"@type":64},"The study examines how gene fusions and rearrangements detected by liquid biopsy (ctDNA) vary across different cancer types and how sensitively actionable events can be identified.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were liquid biopsy and tissue biopsy samples analyzed?",{"text":68,"@type":64},"Liquid biopsy (LBx) from 53,842 patients was profiled using FoundationOneLiquid CDx, while tissue biopsies (TBx) were profiled using FoundationOneCDx as a comparator.",{"name":70,"@type":61,"acceptedAnswer":71},"When do detection rates in LBx become comparable to TBx?",{"text":72,"@type":64},"Detection of driver rearrangements in tissue and LBx was comparable when the tumor fraction (TF) was at least 1%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342515,1790768520,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types  \nPashtoon M. Kasi1, Jessica K. Lee2, Lincoln W. Pasquina2, Brennan Decker2, Pierre Vanden Borre2, Dean C. Pavlick2, Justin M. Allen2, Christine Parachoniak2, Julia C. F. Quintanilha2, Ryon P. Graf2, Alexa B. Schrock2, Geoffrey R. Oxnard2, Christine M. Lovly3, Hanna Tukachinsky2, and Vivek Subbiah4  \nABSTRACT  \n◥  \nPurpose: Genomic rearrangements can generate potent oncogenicdrivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and rearrangements detected by liquid biopsy (LBx)ofcirculating tumor DNA(ctDNA)across different cancer types.  \nExperimental Design: LBx from 53,842 patients with 66 solid tumor types were proﬁled using FoundationOneLiquid CDx, a hybrid-capture sequencing platform that queries 324 cancer-related genes. Tissue biopsies (TBx) proﬁled using FoundationOneCDx were used as a comparator.  \nResults: Among all LBx, 7,377 (14%) had ≥ 1 pathogenic rearrangement detected. A total of 3,648 (6.8%) LBx had ≥ 1 gain-offunction (GOF) oncogene rearrangement, and 4,428 (8.2%) LBx had ≥ 1 loss-of-function rearrangement detected. Cancer types with higher prevalence of GOF rearrangements included those with  \ncanonical fusion drivers: prostate cancer (19%), cholangiocarcinoma (6.4%), bladder (5.5%), and non–small cell lung cancer (4.4%) . Although the prevalence of driver rearrangements was lower in LBx than TBx overall, the frequency of detection was comparable in LBx with a tumor fraction (TF) ≥ 1% . Rearrangements inFGFR2, BRAF, RET, andALK, were detected across cancer types, but tended to be clonal variants in some cancer types and potential acquired resistance variants in others.  \nConclusions: In contrast to some prior literature, this study reports detection ofa wide variety ofrearrangements inctDNA. The prevalence of driver rearrangements in tissue and LBx was comparable whenTF ≥ 1%. LBx presents a viable alternative when TBx isnot available, and there may be less value in conﬁrmatory testing when TF is sufﬁcient.  \nIntroduction  \nDetection of genomic rearrangements in circulating tumor DNA (ctDNA) is heterogeneous across various commercially available and lab developed liquid biopsy (LBx) assays, with multiple reports of variable performance for the detection of these common genomic events (1–3) . Some of these structural variants—deletions, duplications, inversions, and translocations—result in gene products that function as potent oncogenic drivers. Receptor tyrosine kinase (RTK) fusions and activating truncations are well-established targetable driver alterations in non–small cell lung cancer (NSCLC; ALK, RET, ROS1), cholangiocarcinoma (FGFR2), bladder cancer (FGFR3), and  \n1Weill Cornell Medicine, Englander Institute of Precision Medicine, New York Presbyterian Hospital, New York, New York. 2Foundation Medicine, Inc., Cambridge, Massachusetts. 3Vanderbilt University Medical Center, Nashville, Tennessee. 4The University of Texas MD Anderson Cancer Center, Houston, Texas.  \nP. M. Kasi and J. K. Lee contributed equally as co-ﬁrst authors. H. Tukachinsky and V. Subbiah contributed equally as co-last authors.  \nPrior presentations: The results were presented in part as an oral abstract at the ISLB conference, Miami, FL, October 20–22, 2022; and at the ASCO meeting, Chicago, IL, June 2–6, 2023 .  \nCorresponding Authors: Hanna Tukachinsky, Clinical Development, Foundation Medicine, 150 Second St, Cambridge, MA, 02141; E-mail:  \n[htukachinsky@foundationmedicine.com](htukachinsky@foundationmedicine.com); and Pashtoon M. Kasi, E-mail: [pmk4001@med.cornell.edu](pmk4001@med.cornell.edu)  \n[Clin Cancer Res 2024](Clin Cancer Res 2024);[30:836](30:836)–[48](48)  \n[doi:](doi: 10.1158/1078-0432.CCR-23-2693)[ 10.1158/1078-0432.CCR-23-2693](doi: 10.1158/1078-0432.CCR-23-2693)  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives ","cbCaiiq6Qzy5YSLt","https://ap.wps.com/l/cbCaiiq6Qzy5YSLt","pdf",9858441,13,"English","# Abstract\n## Purpose\n## Experimental Design\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What question does the study address about circulating tumor DNA?\",\"answer\":\"The study examines how gene fusions and rearrangements detected by liquid biopsy (ctDNA) vary across different cancer types and how sensitively actionable events can be identified.\"},{\"question\":\"How were liquid biopsy and tissue biopsy samples analyzed?\",\"answer\":\"Liquid biopsy (LBx) from 53,842 patients was profiled using FoundationOneLiquid CDx, while tissue biopsies (TBx) were profiled using FoundationOneCDx as a comparator.\"},{\"question\":\"When do detection rates in LBx become comparable to TBx?\",\"answer\":\"Detection of driver rearrangements in tissue and LBx was comparable when the tumor fraction (TF) was at least 1%.\"}]","Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types | PDF",1790046933,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbe4a8d7f717d093894582a3df19da51.webp",983,1286,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ec2ce9df18dd505b5fcfe34fe7ebdcb.webp",982,1285,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57873d5a2724f93118f3a53fe123bcb2.webp",981,1283,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0583946121e64904b3c392340ceaf03.webp",980,1282]